Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a
medical aesthetics company uniquely focused on plastic surgeons,
today announced its AlloX2 tissue expander has been awarded an
Innovative Technology contract from Vizient, Inc., the nations’
largest member-driven health care performance improvement company.
The contract went into effect May 1 and signifies to Vizient
members the AlloX2’s unique qualities that potentially bring
improvement to the health care industry.
Innovative Technology contracts are awarded
based on the recommendations of health care experts serving on a
Vizient member-led council who review product submissions through
Vizient’s Innovative Technology Program. Councils identify
technologies that have the potential to enhance clinical care,
patient safety, health care worker safety or improve business
operations of health care organizations.
Sientra’s AlloX2’s one of a kind dual-port
design allows for less invasive, non-surgical draining of serous
fluids. The AlloX2 is the only tissue expander on the market with
an integral drain providing direct access to the periprosthetic
space where fluid can accumulate. This allows for diagnostic fluid
sampling to enable a faster treatment response. The AlloX2 was
innovatively designed to mitigate risks associated with breast
expansion and ultimately reduce reoperation rates.
“We are delighted to receive an Innovative
Technology contract, as it highlights the importance of the
transformative technology in our AlloX2 product,” said Ron Menezes,
President and Chief Executive Officer of Sientra. “Vizient serves
more than 50% of the nation’s acute care providers. With this
contract award, Sientra’s AlloX2 is now on contract with all major
GPOs in the nation and available to all reconstruction hospitals in
the US. As COVID restrictions ease, our dedicated reconstruction
team is well prepared to accelerate further pull through into
hospitals and surgery centers under this award.”
“After reviewing feedback on AlloX2 at our
Innovative Technology Exchange, our member council agreed this
solution deserves the Innovative Technology contract.
Congratulations to Sientra on receiving this status,” said Debbie
Archer, Director of Procurement and Vizient Innovative Technology
Program leader.
Vizient represents a diverse membership that
includes academic medical centers, pediatric facilities, community
hospitals, integrated health delivery networks and non-acute health
care providers and represents more than $100 billion in annual
purchasing volume. Through its Innovative Technology Program,
Vizient works with member-led councils and task forces to review
potentially innovative products. If it is determined that a product
is innovative, Vizient may award a contract outside of the
competitive bid cycle.
About SientraHeadquartered in
Santa Barbara, California, Sientra is a medical aesthetics company
uniquely focused on plastic surgeons. The Company mission is to
offer proprietary innovations and unparalleled partnerships that
radically advance how plastic surgeons think, work and care for
their patients. Sientra has developed a broad portfolio of products
with technologically differentiated characteristics, supported by
independent laboratory testing and strong clinical trial outcomes.
The Company’s Breast Products Segment includes its Sientra round
and shaped breast implants, the first fifth generation breast
implants approved by the FDA for sale in the United States, its
ground-breaking Allox2® breast tissue expander with patented
dual-port and integral drain technology, and BIOCORNEUM®, the #1
performing, preferred and recommended scar gel of plastic
surgeons(*). The Company’s miraDry Segment, comprised of its
miraDry® system, is approved for sale in over 56 international
markets and is the only non-surgical, FDA-cleared device indicated
for the permanent reduction of underarm sweat and hair and may also
reduce odor.
Sientra uses its investor relations website
to publish important information about the Company, including
information that may be deemed material to investors. Financial and
other information about Sientra is routinely posted and
is accessible on the Company’s investor relations website
at www.sientra.com.
(*) Data on file
Forward-Looking Statement
This press release contains “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, based on management’s current assumptions and
expectations of future events and trends, which affect or may
affect Sientra’s business, strategy, operations or financial
performance, and actual results may differ materially from those
expressed or implied in such statements due to numerous risks and
uncertainties. Forward-looking statements are made only as of the
date of this release. The words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’
‘‘could,’’ ‘‘will,’’ ‘‘aim,’’ ‘‘estimate,’’ ‘‘continue,
‘‘anticipate,’’ ‘‘intend,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or
the negative of those terms, and similar expressions that convey
uncertainty of future events or outcomes are intended to identify
estimates, projections and other forward-looking statements.
Forward-looking statements may include information concerning the
impact of the COVID-19 pandemic on the Company’s business, the
timing of the easing of COVID-19 restrictions, future popularity of
breast reconstruction procedures, and the ability of Sientra to
pull through into hospitals and surgery centers. Such statements
are subject to risks and uncertainties, including the continuing
popularity breast reconstruction procedures, Sientra’s ability to
recapture delayed procedures resulting from the COVID-19 pandemic,
the positive reaction from plastic surgeons and their patients to
Sientra’s Breast Products, the positive reaction from plastic
surgeons and patients to Sientra’s marketing, sales and educational
programs, and the ability to execute on the Company’s commercial,
product development and manufacturing initiatives, and the ability
of Sientra to obtain contracts with hospitals and surgery centers.
Additional factors that could cause actual results to differ
materially from those contemplated in this press release can be
found in the Risk Factors section of Sientra’s public filings with
the Securities and Exchange Commission. All statements other than
statements of historical fact are forward-looking statements. The
words ‘‘believe,’’ ‘‘may,’’ ‘‘might,’’ ‘‘could,’’ ‘‘will,’’
‘‘aim,’’ ‘‘estimate,’’ ‘‘continue, ‘‘anticipate,’’ ‘‘intend,’’
‘‘expect,’’ ‘‘plan,’’ ‘‘position,” or the negative of those terms,
and similar expressions that convey uncertainty of future events or
outcomes are intended to identify estimates, projections and other
forward-looking statements. You are cautioned not to place undue
reliance on these forward-looking statements, and such estimates,
projections and other forward-looking statements speak only as of
the date they were made, and, except to the extent required by law,
the Company undertakes no obligation to update or review any
estimate, projection or forward-looking statement. Actual results
may differ from those set forth in this press release due to the
risks and uncertainties inherent in the Company’s business.
Investor Relations ContactLeigh
Salvoir@sientra.com
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sientra (NASDAQ:SIEN)
Historical Stock Chart
From Sep 2023 to Sep 2024